John C. Molina, MD, EdM, reviews data from the 3-year update from the OPTIC study, and other experts offer their impressions.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Zanubrutinib Shows Enhanced Efficacy vs Approved BTKis in R/R CLL
A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
HSCT Recipients Show Sustained Health Challenges Following Transplant
Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
Highlighting Developments and Informing Treatment Planning in CLL Care
Clinical guidelines aimed at both clinicians and patients seek to educate and include both parties in clinical decision-making processes.
CHMP Recommends Pirtobrutinib for EU Approval in Pretreated R/R CLL
Pirtobrutinib demonstrated PFS benefit compared with standard of care in patients with relapsed or refractory CLL in the BRUIN CLL-321 trial.